Axsome Therapeutics Quarterly Income Statement
NASDAQ: AXSMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Axsome Therapeutics revenue and earnings
In the quarter ended Jun 30, 2026, Axsome Therapeutics generated $218.4 million in revenue, up 45.5% from the same quarter a year earlier. Axsome Therapeutics reported a net loss of $51.3 million, compared with a loss of $48.0 million a year earlier. Gross margin was 93.8% (up from 91.0%) and operating margin -22.7%.
Diluted earnings per share came in at -$0.99.
Summary generated from market data by MetaCap's automated system. Methodology
Axsome Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 218.38M | 191.20M | 196.00M | 170.99M | 150.04M | 121.46M | 118.77M | 104.76M | 87.17M | 75.00M | 71.53M | 57.79M |
| Revenue growth (YoY) | +45.54% | +57.42% | +65.03% | +63.22% | +72.13% | +61.95% | +66.04% | +81.27% | +86.65% | -20.70% | +193.50% | +243.07% |
| Cost of Revenue | 13.56M | 14.72M | 12.33M | 11.91M | 13.45M | 9.79M | 10.51M | 8.44M | 8.05M | 6.30M | 7.38M | 6.53M |
| Gross Profit | 204.81M | 176.48M | 183.67M | 159.08M | 136.59M | 111.67M | 108.25M | 96.33M | 79.11M | 68.70M | 64.15M | 51.26M |
| Operating Expenses | 254.46M | 239.84M | 210.63M | 205.19M | 173.31M | 168.66M | 180.87M | 158.95M | 157.16M | 135.98M | 162.43M | 113.38M |
| Research & Development | 46.23M | 52.68M | 48.79M | 40.16M | 49.54M | 44.78M | 55.01M | 45.39M | 49.85M | 36.83M | 30.80M | 28.77M |
| Selling, General & Admin | 208.14M | 185.00M | 169.30M | 150.24M | 130.28M | 120.79M | 113.27M | 95.56M | 103.55M | 98.97M | 86.81M | 83.19M |
| Operating Income | -49.65M | -63.36M | -26.96M | -46.11M | -36.71M | -56.98M | -72.62M | -62.62M | -78.05M | -67.28M | -98.27M | -62.12M |
| Interest Expense | -3.20M | 3.09M | -3.21M | -3.38M | -4.09M | 5.26M | -5.43M | -5.67M | -5.08M | -5.41M | — | — |
| Pretax Income | -51.19M | -64.54M | -28.13M | -47.23M | -48.93M | -59.41M | -74.83M | -64.60M | -79.34M | -68.36M | -98.98M | -62.88M |
| Income Tax | 128.00K | 0 | 430.00K | 0 | -960.00K | 0 | 85.00K | 0 | 0 | 0 | -325.00K | -678.00K |
| Net Income | -51.31M | -64.54M | -28.56M | -47.23M | -47.97M | -59.41M | -74.91M | -64.60M | -79.34M | -68.36M | -98.65M | -62.20M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.99 | -1.26 | -0.55 | -0.94 | -0.97 | -1.22 | -1.54 | -1.34 | -1.67 | -1.44 | -2.15 | -1.32 |
| EPS (Diluted) | -0.99 | -1.26 | -0.55 | -0.94 | -0.97 | -1.22 | -1.54 | -1.34 | -1.67 | -1.44 | -2.15 | -1.32 |
| Shares Outstanding (Basic) | 51.80M | 51.20M | — | 50.02M | 49.44M | 48.87M | — | 48.14M | 47.57M | 47.39M | — | 47.12M |
| Shares Outstanding (Diluted) | 51.80M | 51.20M | — | 50.02M | 49.44M | 48.87M | — | 48.14M | 47.57M | 47.39M | — | 47.12M |
| EBITDA | -49.50M | -63.24M | -26.84M | -45.99M | -36.59M | -56.83M | -72.49M | -62.49M | -77.91M | -67.14M | -98.14M | -61.98M |
| Gross Margin | 93.79% | 92.30% | 93.71% | 93.03% | 91.04% | 91.94% | 91.15% | 91.95% | 90.76% | 91.60% | 89.69% | 88.70% |
| Operating Margin | -22.73% | -33.14% | -13.75% | -26.97% | -24.47% | -46.91% | -61.14% | -59.78% | -89.54% | -89.70% | -137.39% | -107.49% |
| Net Margin | -23.50% | -33.76% | -14.57% | -27.62% | -31.97% | -48.91% | -63.08% | -61.67% | -91.03% | -91.14% | -137.92% | -107.62% |
This table shows 12 quarterly periods of Axsome Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow AXSM's reporting calendar. What is a income statement?